^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Adenocarcinoma

    Related cancers:
    1d
    LEAH: Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (clinicaltrials.gov)
    P=N/A, N=5909, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)
    |
    TP53 mutation • PTEN deletion
    6d
    Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (clinicaltrials.gov)
    P3, N=895, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • oxaliplatin • levoleucovorin calcium
    6d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=184, Recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • pumitamig (BNT327)
    6d
    CP-IVX001: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=70, Recruiting, ImmVirx Pty Ltd | Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Sep 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Tyvyt (sintilimab) • IVX037
    8d
    A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Astellas Pharma Global Development, Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 expression
    12d
    Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients (clinicaltrials.gov)
    P1, N=33, Completed, Arbele Pty Ltd | Recruiting --> Completed | N=68 --> 33 | Trial completion date: May 2026 --> Jul 2025 | Trial primary completion date: Mar 2026 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CDH17 (Cadherin 17)
    |
    Tecentriq (atezolizumab) • cabotamig (ARB202)
    12d
    A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=310, Recruiting, Pfizer
    Trial initiation date
    14d
    HER-OIC: Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer (clinicaltrials.gov)
    P1/2, N=29, Not yet recruiting, Universitaire Ziekenhuizen KU Leuven
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Tevimbra (tislelizumab-jsgr) • Ziihera (zanidatamab-hrii)
    14d
    Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Sep 2026 --> Mar 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    15d
    Integrative Transcriptomic Profiling Reveals Molecular Signatures of Disease Progression from Gastroesophageal Reflux Disease to Barrett's Esophagus: A Foundation for Single-Cell Resolution Studies. (PubMed, SLAS Technol)
    This comprehensive transcriptomic study unveils the molecular complexity underlying GERD-to-Barrett's esophagus progression, identifying key genes and pathways that drive pathological transformation.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CDH17 (Cadherin 17) • MMP7 (Matrix metallopeptidase 7)
    16d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=131, Recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    20d
    WEE1 Stabilizes MYC to Promote Therapeutic Resistance in Esophageal Adenocarcinoma. (PubMed, Cancer Lett)
    These findings reveal a novel cytoplasmic function of WEE1 in sustaining MYC stability and chemoresistance. Targeting WEE1 destabilizes MYC and enhances therapeutic response, supporting the combination of MK-1775 and Panobinostat as a promising treatment strategy for EAC.
    Journal
    |
    ABCC1 (ATP Binding Cassette Subfamily C Member 1) • MSH3 (MutS Homolog 3) • CDK1 (Cyclin-dependent kinase 1)
    |
    adavosertib (AZD1775) • Farydak (panobinostat)